Floatz logo

Therapeutic Asset Ratings

91,565 assets7,904 sponsors3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Nivolumab
Hodgkins Lymphoma
M.D. Anderson Cancer CenterP3BBB (72)
Nivolumab
Liver Cancer
M.D. Anderson Cancer CenterP3BBB (72)
Nivolumab
Renal Pelvis Urothelial Carcinoma
National Cancer Institute (NCI)P3BBB (72)
Nivolumab
Ureter Transitional Cell Carcinoma
Alliance for Clinical Trials in OncologyP3BBB (72)
Nivolumab
Urethra Transitional Cell Carcinoma
Nagoya UniversityP3BBB (72)
Nivolumab
Colon Adenocarcinoma
IFOM ETS - The AIRC Institute of Molecular OncologyP3BBB (72)
Nivolumab
Uveal Melanoma
Inge Marie SvaneP3BBB (72)
Nivolumab
Primary Peritoneal Carcinoma
Regeneron PharmaceuticalsP3BBB (72)
Nivolumab
Sarcomatoid Renal Cell Carcinoma
City of Hope Medical CenterP3BBB (72)
Nogitecan
Ovarian Serous Adenocarcinoma
National Cancer Institute (NCI)P3BBB (72)
Nrx-101
Bipolar Depression
NeuroRx, Inc.P3BBB (72)
Obinutuzumab
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
M.D. Anderson Cancer CenterP3BBB (72)
Oxaliplatin
Chemotherapy-Induced Toxicity
Linhui PengP3BBB (72)
Oxaliplatin
Primary Peritoneal Carcinoma
National Cancer Institute (NCI)P3BBB (72)
Pegargiminase
Hepatocellular Carcinoma
Chang Gung Memorial HospitalP3BBB (72)
Pembrolizumab
Acute Myeloid Leukemia
Joanna YiP3BBB (72)
Pembrolizumab
Brain Neoplasm
Essen BiotechP3BBB (72)
Pembrolizumab
Breast Cancer
West German Study GroupP3BBB (72)
Pembrolizumab
Breast Neoplasm
Merck Sharp & Dohme LLCP3BBB (72)
Pembrolizumab
Classic Hodgkin Lymphoma
National Cancer Institute (NCI)P3BBB (72)
Pembrolizumab
Nonpapillary Renal Cell Carcinoma
City of Hope Medical CenterP3BBB (72)
Pembrolizumab
Endometrial Carcinoma
Eikon TherapeuticsP3BBB (72)
Pembrolizumab
Ovarian Carcinoma
Roswell Park Cancer InstituteP3BBB (72)
Pembrolizumab
Esophageal Squamous Cell Carcinoma
GV20 TherapeuticsP3BBB (72)
Pembrolizumab
Breast Carcinoma
The Netherlands Cancer InstituteP3BBB (72)
Showing 2126 to 2150 of 42,286 assets
PreviousPage 86 of 1692Next